MHRA Drug Safety Update April 2019

MHRA Drug Safety Update April 2019

April 17, 2019

Date issued: 16th April 2019

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 12 Issue 9 March 2019:1) has been published and includes articles on:

  • Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those 60 years and older.
  • Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme.
  • Belimumab (Benlysta ▼) : Increased risk of serious psychiatric events seen in clinical trials.
  • Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April 2019.
  • Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
  • Letters and drug alerts sent to healthcare professionals in March 2019
  • Medical Device Alerts issued in March 2019

To see the latest MHRA Drug Safety Update in full, visit the GOV.uk website.

 



Posted in:


More Latest News >

Shortage Notice: Salbutamol 2mg/5ml syrup

GlaxoSmithKline (GSK) and Pinewood, the manufacturers of Salbutamol 2mg/5ml syrup, are currently experiencing temporary disruptions. GSK, the main supplier of Salbutamol...